RNA
BEARISH
$14.41
Live
Atrium Therapeutics, Inc. · NASDAQ
Target $25.0
(+73.5%)
$11.95
52W Range
$16.77
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Apr 19, 2026
Market cap
$223.57M
P/E
N/A
ROE
N/A
Profit margin
-265.9%
Debt/Equity
N/A
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
95%
RNA exhibits critical financial distress, characterized by a Piotroski F-Score of 4/9 which barely maintains a 'stable' rating despite catastrophic liquidity metrics. The company is facing a severe solvency crisis with a Current Ratio of 0.07 and a negative Price/Book ratio of -3.57, indicating negative shareholders' equity. Revenue has collapsed by 71.10% YoY, and the company has missed earnings estimates in 100% of the last four quarters. Combined with aggressive insider selling by the CEO and CFO, the fundamental outlook is extremely poor.
Key Strengths
Recent short-term price momentum (+17% in 1 month)
Single analyst target price of $25.00 suggests potential speculative upside
Market capitalization remains above $200M despite losses
Piotroski F-Score of 4/9 prevents a 'weak' classification
Operating in the high-growth Healthcare/Biotech sector
Key Risks
Extreme liquidity risk (Current Ratio 0.07, Quick Ratio 0.00)
Negative equity (Price/Book -3.57) indicating insolvency risk
Severe revenue contraction (-71.10% YoY)
Heavy insider selling (13 sell transactions, 0 buys)
Consistent earnings misses with widening losses
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
10
Weak
5
10
20
15
0
AI Verdict
High Risk / Avoid
Key drivers: Insolvency risk due to near-zero liquidity, Collapsing top-line revenue, Negative book value, Bearish insider sentiment
Confidence
95%
Value
5/100
Ref P/E, PEG, Graham Number
Positives
No standout positives identified.
Watchpoints
- Price/Book is -3.57
- Price/Sales is 12.01x despite revenue decline
- No Graham Number available due to lack of earnings
Future
10/100
Ref Growth rates
Positives
No standout positives identified.
Watchpoints
- Revenue Growth -71.10%
- EPS Growth -98.8%
- Forward P/E remains negative
Past
20/100
Ref Historical trends
Positives
- Some historical earnings beats in 2023-2024
Watchpoints
- 0/4 beats in the most recent 4 quarters
- Average surprise of -22.68% recently
Health
15/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- Piotroski F-Score 4/9
Watchpoints
- Current Ratio 0.07 is critically low
- Quick Ratio 0.00 indicates no liquid assets
- Negative ROA of -399.25%
Dividend
0/100
Ref Yield, Payout
Positives
No standout positives identified.
Watchpoints
- No dividend paid
- 0/100 dividend strength
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$14.41
Analyst Target
$25.0
Upside/Downside
+73.5%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for RNA and closest competitors.
Updated 2026-04-17
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
RNA
Atrium Therapeutics, Inc.
Primary
|
-2.3% | -2.3% | -2.3% | -2.3% | +17.0% | +13.4% |
|
OSUR
OraSure Technologies, Inc.
Peer
|
-67.6% | -52.3% | +10.6% | +5.9% | +3.5% | +5.2% |
|
SGHT
Sight Sciences, Inc.
Peer
|
-87.8% | -52.7% | +53.8% | -12.8% | +10.8% | +18.6% |
|
MGNX
MacroGenics, Inc.
Peer
|
-88.9% | -46.5% | +173.2% | +111.6% | +15.7% | +9.1% |
|
MDWD
MediWound Ltd.
Peer
|
-51.4% | +35.6% | +6.4% | -3.1% | +6.5% | +6.8% |
RNA
Atrium Therapeutics, Inc.
Primary
5Y
-2.3%
3Y
-2.3%
1Y
-2.3%
6M
-2.3%
1M
+17.0%
1W
+13.4%
OSU
OraSure Technologies, Inc.
Peer
5Y
-67.6%
3Y
-52.3%
1Y
+10.6%
6M
+5.9%
1M
+3.5%
1W
+5.2%
SGH
Sight Sciences, Inc.
Peer
5Y
-87.8%
3Y
-52.7%
1Y
+53.8%
6M
-12.8%
1M
+10.8%
1W
+18.6%
MGN
MacroGenics, Inc.
Peer
5Y
-88.9%
3Y
-46.5%
1Y
+173.2%
6M
+111.6%
1M
+15.7%
1W
+9.1%
MDW
MediWound Ltd.
Peer
5Y
-51.4%
3Y
+35.6%
1Y
+6.4%
6M
-3.1%
1M
+6.5%
1W
+6.8%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
-3.57
PEG Ratio
N/A
P/B Ratio
-3.57
P/S Ratio
12.01
EV/Revenue
N/A
EV/EBITDA
N/A
Market Cap
$223.57M
Profitability
Profit margins and return metrics
Profit Margin
-265.88%
Operating Margin
-3387.89%
Gross Margin
-137.77%
ROE
N/A
ROA
-399.25%
Growth
Revenue and earnings growth rates
Revenue Growth
-71.1%
Earnings Growth
N/A
Q/Q Revenue Growth
N/A
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
N/A
Current Ratio
0.07
Weak
Quick Ratio
0.0
Poor
Cash/Share
$N/A
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Revenue
$0.0B
Op. Margin
-5592.0%
Net Margin
-5595.9%
Total Assets
$0.3B
Liabilities
$0.1B
Equity
$0.2B
Debt/Equity
0.34x
Operating CF
$-0.0B
CapEx
$-0.0B
Free Cash Flow
$-0.0B
FCF Yield
105%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-05-11
$N/A
2026-02-23
$-1.59
-26.4% surprise
2025-11-10
$-1.27
-15.3% surprise
2025-08-07
$-1.21
-26.3% surprise
Healthcare Sector Comparison
Comparing RNA against 447 companies in the Healthcare sector
(26 bullish, 140 neutral, 281 bearish)
Profit Margin
-265.88%
This Stock
vs
-14.95%
Sector Avg
+1678.4%
(Superior)
Revenue Growth
-71.1%
This Stock
vs
147.85%
Sector Avg
-148.1%
(Slower)
Current Ratio
0.07
This Stock
vs
4.68
Sector Avg
-98.5%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
RNA
Atrium Therapeutics, Inc.
|
BEARISH | $223.57M | - | -% | -265.9% | $14.41 | |
|
OSUR
OraSure Technologies, Inc.
|
BEARISH | $223.97M | - | -18.3% | -59.8% | $3.24 | Compare |
|
SGHT
Sight Sciences, Inc.
|
BEARISH | $220.88M | - | -50.7% | -49.7% | $4.09 | Compare |
|
MGNX
MacroGenics, Inc.
|
BEARISH | $220.55M | - | -86.9% | -49.9% | $3.47 | Compare |
|
MDWD
MediWound Ltd.
|
BEARISH | $226.84M | - | -63.9% | -140.8% | $17.65 | Compare |
RNA
Atrium Therapeutics, Inc.
BEARISH
Mkt Cap
$224M
P/E
-
ROE
-%
Price
$14.41
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-01-21 | LEVIN ARTHUR A. | Director | Sale | 1,758 | $127,367 |
| 2026-01-21 | MACLEAN MICHAEL F. | Chief Financial Officer | Sale | 4,542 | $329,068 |
| 2026-01-21 | BOYCE SARAH | Chief Executive Officer | Sale | 14,387 | $1,042,338 |
| 2026-01-21 | HUGHES STEVEN GEORGE | Officer | Sale | 4,895 | $354,643 |
| 2026-01-21 | FLANAGAN WILLIAM MICHAEL | Officer | Sale | 6,534 | $473,388 |
| 2026-01-21 | MCCARTHY TERESA | Officer | Sale | 2,929 | $212,206 |
| 2026-01-07 | MACLEAN MICHAEL F. | Chief Financial Officer | Sale | 1,974 | $142,582 |
| 2026-01-07 | MORIARTY JOHN B | Officer | Sale | 2,374 | $171,474 |
| 2026-01-07 | BOYCE SARAH | Chief Executive Officer | Sale | 8,576 | $619,444 |
| 2026-01-07 | HUGHES STEVEN GEORGE | Officer | Sale | 2,373 | $171,402 |
| 2026-01-07 | FLANAGAN WILLIAM MICHAEL | Officer | Sale | 2,373 | $171,402 |
| 2026-01-07 | MCCARTHY TERESA | Officer | Sale | 1,965 | $141,932 |
| 2026-01-07 | CALDERARO CHARLES III | Officer | Sale | 3,727 | $269,201 |
| 2025-12-19 | LEVIN ARTHUR A. | Director | Gift | 1,330 | - |
| 2025-12-18 | BOYCE SARAH | Chief Executive Officer | Gift | 29,159 | - |
LEVIN ARTHUR A.
Director
2026-01-21
1,758 shares
·
$127,367
MACLEAN MICHAEL F.
Chief Financial Officer
2026-01-21
4,542 shares
·
$329,068
BOYCE SARAH
Chief Executive Officer
2026-01-21
14,387 shares
·
$1,042,338
HUGHES STEVEN GEORGE
Officer
2026-01-21
4,895 shares
·
$354,643
FLANAGAN WILLIAM MICHAEL
Officer
2026-01-21
6,534 shares
·
$473,388
MCCARTHY TERESA
Officer
2026-01-21
2,929 shares
·
$212,206
MACLEAN MICHAEL F.
Chief Financial Officer
2026-01-07
1,974 shares
·
$142,582
MORIARTY JOHN B
Officer
2026-01-07
2,374 shares
·
$171,474
BOYCE SARAH
Chief Executive Officer
2026-01-07
8,576 shares
·
$619,444
HUGHES STEVEN GEORGE
Officer
2026-01-07
2,373 shares
·
$171,402
FLANAGAN WILLIAM MICHAEL
Officer
2026-01-07
2,373 shares
·
$171,402
MCCARTHY TERESA
Officer
2026-01-07
1,965 shares
·
$141,932
CALDERARO CHARLES III
Officer
2026-01-07
3,727 shares
·
$269,201
LEVIN ARTHUR A.
Director
2025-12-19
1,330 shares
BOYCE SARAH
Chief Executive Officer
2025-12-18
29,159 shares
Insider transactions can signal confidence or concerns about company prospects
SEC Filings
Recent regulatory filings from the SEC EDGAR database
Data sourced from SEC EDGAR. AI summaries generated automatically.
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
NONE
1 analysts
Wells Fargo
2026-03-11
Overweight
Chardan Capital
2025-11-11
Neutral
Neutral
TD Cowen
2025-10-29
Buy
Hold
Chardan Capital
2025-10-28
Buy
Neutral
RBC Capital
2025-10-28
Outperform
Sector Perform
Citigroup
2025-10-27
Buy
Neutral
Leerink Partners
2025-10-27
Outperform
Market Perform
Raymond James
2025-10-27
Strong Buy
Market Perform
Bernstein
2025-10-27
Outperform
Market Perform
Needham
2025-10-27
Buy
Hold
Past News Coverage
Recent headlines mentioning RNA from our newsroom.
Newest → oldest
No matching news yet.